-
EP3697773
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3697773
| EP3697773 - PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 27.05.2022 Database last updated on 19.07.2024 | |
| Former | Request for examination was made Status updated on 24.07.2020 | ||
| Former | The international publication has been made Status updated on 26.04.2019 | ||
| Former | unknown Status updated on 17.11.2018 | Most recent event Tooltip | 29.05.2024 | New entry: Application deemed to be withdrawn: despatch of communication + time limit | Applicant(s) | For all designated states Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE | [2022/18] |
| Former [2020/35] | For all designated states Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE | Inventor(s) | 01 /
KARRA, Srinivasa R. 58 Four Winds Drive Pembroke Massachusetts 02359 / US | 02 /
XIAO, YuFang 11 Ames Avenue Lexington Massachusetts 02421 / US | 03 /
SHERER, Brian A. 57 Harris Road Nashua New Hampshire 03062 / US | 04 /
CHEKLER, Eugene 2112 main Street Concord, Massachusetts 01742 / US | [2020/35] | Application number, filing date | 18797387.0 | 17.10.2018 | [2020/35] | WO2018US56192 | Priority number, date | US201762573255P | 17.10.2017 Original published format: US 201762573255 P | [2020/35] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019079375 | Date: | 25.04.2019 | Language: | EN | [2019/17] | Type: | A1 Application with search report | No.: | EP3697773 | Date: | 26.08.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.04.2019 takes the place of the publication of the European patent application. | [2020/35] | Search report(s) | International search report - published on: | EP | 25.04.2019 | Classification | IPC: | C07D401/14, C07D405/14, C07D413/14, A61P29/00, A61K31/497 | [2020/35] | CPC: |
C07D405/14 (EP,IL,KR,US);
C07D401/14 (EP,IL,US);
A61K31/506 (KR);
A61P19/02 (KR);
A61P19/10 (KR);
A61P29/00 (EP,IL,KR);
A61P3/10 (KR);
C07D413/14 (EP,IL,KR);
C07D419/14 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/35] | Title | German: | PYRIMIDIN-TBK/IKKE-INHIBITORVERBINDUNGEN UND IHRE VERWENDUNG | [2020/35] | English: | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | [2020/35] | French: | COMPOSÉS INHIBITEURS TBK/IKKe PYRIMIDINE ET LEURS UTILISATIONS | [2020/35] | Entry into regional phase | 14.04.2020 | National basic fee paid | 14.04.2020 | Designation fee(s) paid | 14.04.2020 | Examination fee paid | Examination procedure | 14.04.2020 | Examination requested [2020/35] | 14.04.2020 | Date on which the examining division has become responsible | 27.11.2020 | Amendment by applicant (claims and/or description) | 31.05.2022 | Despatch of a communication from the examining division (Time limit: M06) | 08.12.2022 | Reply to a communication from the examining division | 28.05.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time | Fees paid | Renewal fee | 14.10.2020 | Renewal fee patent year 03 | 29.09.2021 | Renewal fee patent year 04 | 15.09.2022 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 31.10.2023 | 06 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2004089286 (IRM LLC [US], et al) [X] 1-4,7-11,13,16 * compound 11 on page 41; claim 1; *; | [X]US2005203092 (BENJAMIN ELFRIDA R [US], et al) [X] 1-3,5,7-11,13,16 * compounds 62 and 64 on page 22; *; | [XI]WO2006125616 (INGENIUM PHARMACEUTICALS AG [DE], et al) [X] 1-5,7-11,13,15-19 * compound 163 on page 109; compound 209 on page 112, claim 5;Figure 4; page 2, lines 26ff * [I] 1-20; | [XI]WO2013175415 (PIRAMAL ENTPR LTD [IN]) [X] 1-3,5,7-11,13,14,16,18-20 * compound on paage 29, line 11, claim 1; description pages 43-44; * [I] 1-20; | [X]WO2017114510 (SHANGHAI INST MATERIA MEDICA CAS [CN], et al) [X] 1,2,5,7,10,11,16* compound A225 on page 105; * | by applicant | - WEINSTEIN-OPPENHEIMER et al., Pharma. &. Therap., (20000000), vol. 88, pages 229 - 279 | - J.S. BOEHM et al., Cell, (20070000), vol. 129, pages 1065 - 1079 | - S.F.EDDY et al., Cancer Res., (20050000), vol. 65, no. 24, pages 11375 - 11383 | - C.KORHERR et al., PNAS, (20060000), vol. 103, pages 4240 - 4245 | - Y.CHIEN et al., Cell, (20060000), vol. 127, pages 157 - 170 | - Handbook of Chemistry and Physics | - S. M. BERGE et al., J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19 |